Therapeutic efficacy of the combination of doxorubicin-loaded liposomes with inertial cavitation generated by confocal ultrasound in AT2 Dunning rat tumour model

References

• Dromi S, Frenkel V, Luk A, et al. Pulsed high-intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Research 2007;13:2722–7
   PubMed Web of Science ®Google Scholar
• Gabizon A, Goren D, Horowitz A, et al. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv Drug Deliv Rev 1997;24:337–44
   Web of Science ®Google Scholar
• Li L, ten Hagen TLM, Hossann M, et al. Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy. J Control Release 2013;168:142–50
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda, H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin. Clin Pharmacokinetics 2003;42:419–36
   PubMed Web of Science ®Google Scholar
• Fang J, Nakamura, H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011;63:136–51
   PubMed Web of Science ®Google Scholar
• O’Brien MER. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440–9
   PubMed Web of Science ®Google Scholar
• Pisano C, Cecere SC, Di Napoli M, et al. Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer. J Drug Deliv 2013;2013:898146. doi: 10.1155/2013/898146
   Google Scholar
• Régnier-Rosencher E, Guillot, B, Dupin N. Treatments for classic Kaposi sarcoma: a systematic review of the literature. J Am Acad Dermatol 2013;68:313–31
   PubMed Web of Science ®Google Scholar
• Sparano J, Malik, U, Rajdev L. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer. J Clin Oncol 2001;19:3117–25
   PubMed Web of Science ®Google Scholar
• Safra T, Muggia, F, Jeffers S. Pegylated liposomal doxorubicin: reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000;11:1029–33
   PubMed Web of Science ®Google Scholar
• Ishida T, Kirchmeier M, Moase E, et al. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim Biophys Acta 2001;1515:144–58
   PubMed Web of Science ®Google Scholar
• Hagtvet E, Evjen TJ, Olsen DR, et al. Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice. J Drug target 2011;19:701–8
   PubMed Web of Science ®Google Scholar
• Lafon C, Somaglino L, Bouchoux G, et al. Feasibility study of cavitation-induced liposomal doxorubicin release in an AT2 Dunning rat tumor model. J Drug Targe 2012;20:691–702
   PubMed Web of Science ®Google Scholar
• Choi JJ, Wang S, Tung Y-S, et al. Molecules of various pharmacologically-relevant sizes can cross the ultrasound-induced blood-brain barrier opening in vivo. Ultrasound Med Biol 2010;36:58–67
   PubMed Web of Science ®Google Scholar
• Yudina A, Lepetit-Coiffé M, Moonen CTW. Evaluation of the temporal window for drug delivery following ultrasound-mediated membrane permeability enhancement. Mol Imag Biol 2011;13:239–49
   PubMed Web of Science ®Google Scholar
• Mellal D, Zumbuehl A. Exit-strategies – smart ways to release phospholipid vesicle cargo. J Mater Chem B 2014;2:247 . doi: 10.1039/C3TB21086C
   Web of Science ®Google Scholar
• Oerlemans C, Deckers R, Storm G, et al. Evidence for a new mechanism behind HIFU-triggered release from liposomes. J Control Release 2013;168:327–33
   PubMed Web of Science ®Google Scholar
• Greenleaf WJ, Bolander ME, Sarlar G, et al. Artificial cavitation nuclei significantly enhance acoustically induced cell transfection. Ultrasound Med Biol 1998;24:587–95
   PubMed Web of Science ®Google Scholar
• Koch S, Pohl P, Cobet U, et al. Ultrasound enhancement of liposome-mediated cell transfection is caused by cavitation effects. Ultrasound Med Biol 2000;26:897–903
   PubMed Web of Science ®Google Scholar
• Unger EC, Matsunaga TO, Mccreery T, et al. Therapeutic applications of microbubbles. Eur J Radiol 2002;42:160–8
   PubMed Web of Science ®Google Scholar
• Kheirolomoom A, Dayton PA, Lum AFH, et al. Acoustically-active microbubbles conjugated to liposomes: characterization of a proposed drug delivery vehicle. J Control Release 2007;118:275–84
   PubMed Web of Science ®Google Scholar
• Javadi M, Pitt WG, Tracy CM, et al. Ultrasonic gene and drug delivery using liposomes. J Control Release 2013;167:92–100
   PubMed Web of Science ®Google Scholar
• Negishi Y, Hamano N, Tsunoda Y, et al. AG73-modified Bubble liposomes for targeted ultrasound imaging of tumor neovasculature. Biomaterials 2013;34:501–7
   PubMed Web of Science ®Google Scholar
• Böhmer MR, Klibanov AL, Tiemann K, et al. Ultrasound triggered image-guided drug delivery. Eur J Radiol 2009;70:242–53
   PubMed Web of Science ®Google Scholar
• Feshitan JA, Chen CC, Kwan JJ, et al. Microbubble size isolation by differential centrifugation. Journal J Colloid Interface Sci 2009;329:316–24
   PubMed Web of Science ®Google Scholar
• Tartis MS, Kruse DE, Zheng H, et al. Dynamic microPET imaging of ultrasound contrast agents and lipid delivery. J Control Release 2008;131:160–6
   PubMed Web of Science ®Google Scholar
• Evjen TJ, Nilssen EA, Fowler RA, et al. Lipid membrane composition influences drug release from dioleoylphosphatidylethanolamine-based liposomes on exposure to ultrasound. Int J Pharm 2011;406:114–16
   PubMed Web of Science ®Google Scholar
• Lin H, Thomas JL. PEG – lipids and oligo surfactants enhance the ultrasonic permeabilizability of liposomes. Langmuir 2003;19:1098–105
   Google Scholar
• Evjen TJ, Nilssen EA, Rögnvaldsson S, et al. Distearoylphosphatidylethanolamine-based liposomes for ultrasound-mediated drug delivery. Eur J Pharm Biopharm 2010;75:327–33
   PubMed Web of Science ®Google Scholar
• Jensen CR, Cleveland RO, Coussios CC. Real-time temperature estimation and monitoring of HIFU ablation through a combined modeling and passive acoustic mapping approach. Phys Med Biol 2013;58:5833–50
   PubMed Web of Science ®Google Scholar
• Somaglino L, Bouchoux G, Mestas J-L, et al. Validation of an acoustic cavitation dose with hydroxyl radical production generated by inertial cavitation in pulsed mode: application to in vitro drug release from liposomes. Ultrasonics Sonochem 2011;18:577–88
   PubMed Web of Science ®Google Scholar
• Villeneuve L, Alberti L, Steghens J-P, et al. Assay of hydroxyl radicals generated by focused ultrasound. Ultrasonics Sonochem 2009;16:339–44
   PubMed Web of Science ®Google Scholar
• Komura K, Inamoto T, Takai T, et al. Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy. World J Urol 2013;2–7. doi: 10.1007/s00345-013-1215-z
   Google Scholar
• Pfeiffer D, Berger, J, Gross A. Single application of high-intensity focused ultrasound as a first-line therapy for clinically localized prostate cancer: 5-year outcomes. BJU Int 2012;110:1702–8
   PubMed Web of Science ®Google Scholar
• Evjen TJ, Nilssen EA, Barnert S, et al. Ultrasound-mediated destabilization and drug release from liposomes comprising dioleoylphosphatidylethanolamine. Eur J Pharm Sci 2011;42:380–6
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008;5:505–15
   PubMed Web of Science ®Google Scholar
• Chapelon JY, Margonari J, Vernier F. In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma dunning. Cancer Res 1992;52:6353–7
   Google Scholar
• Paparel P, Curiel L, Chesnais S, et al. Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma. BJU Int 2005;95:881–5
   PubMed Web of Science ®Google Scholar
• Zhigaltsev IV, Maurer N, Wong K, et al. Triggered release of doxorubicin following mixing of cationic and anionic liposomes. Biochim Biophys Acta 2002;1565:129–135
   Google Scholar
• Iida Y, Yasui K, Tuziuti T, et al. Sonochemistry and its dosimetry. Microchem J 2005;80:159–64
   Web of Science ®Google Scholar
• Lafon C, Zderic V, Noble ML, et al. Gel phantom for use in high-intensity focused ultrasound dosimetry. Ultrasound Med Biol 2005;31:1383–9
   PubMed Web of Science ®Google Scholar
• Morris H, Rivens I. Investigation of the viscous heating artefact arising from the use of thermocouples in a focused ultrasound field. Phys Med Biol 2008;53:4759–76
   Google Scholar
• Evjen TJ, Hagtvet E, Moussatov A, et al. In vivo monitoring of liposomal release in tumours following ultrasound stimulation. Eur J Pharm Biopharm 2013;84:526–31
   PubMed Web of Science ®Google Scholar
• Charrois GJR, Allen TM. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta 2004;1663:167–77
   PubMed Web of Science ®Google Scholar
• Evjen TJ, Hagtvet E, Nilssen EA, et al. Sonosensitive dioleoylphosphatidylethanolamine-containing liposomes with prolonged blood circulation time of doxorubicin. Eur J Pharm Sci 2011;43:318–24
   PubMed Web of Science ®Google Scholar
• Wang Y-N, Khokhlova T, Bailey M, et al. Histological and biochemical analysis of mechanical and thermal bioeffects in boiling histotripsy lesions induced by high intensity focused ultrasound. Ultrasound Med Biol 2013;39:424–38
   PubMed Web of Science ®Google Scholar